Abstract:Abstract Background Cystic Fibrosis (CF) is one of the most prevalent severe genetic diseases, with a high economic impact on healthcare systems due to its complexity. The life expectancy of CF patients has substantially lengthened due to early diagnosis and improvements in therapeutic regimens with Cystic fibrosis transmembrane conductance regulator (CFTR) modulators. Therefore, strategies to ensure equitable access to these treatments should be optimized. Our study aimed to summarize existing literature regarding the costs of CF in Europe. Methods A systematic literature review was performed querying three online database (PubMed, Scopus, Web of Science) from January 2013 to March 2023. Studies carried out in European countries, written in English language, and focused on the socio-economic burden of CF were selected. Results Overall, 11 studies were considered. Across countries, the average total annual cost for a CF patient amounted to €14.174,00-53.256,00, higher for children (€15.771-60.412,00) compared to adults (€15.714-€47.217,00). The largest expenditures were recorded for annual direct healthcare costs, which amounted, per patient, to €9861,00-28.827,00, followed by direct non-healthcare costs (€4512,00-18.329,00). For adults, drugs, tests, and hospitalizations represented the primary cost drivers of direct healthcare costs, while for children, direct non-healthcare costs, especially for caregivers, were predominant. Moreover, indirect costs, whose main expenses were related to productivity loss and early retirement, ranged between €1,094-12,443 per patient per year. Conclusions The CF management is associated with relevant costs. CFTR modulators represent an important therapeutic opportunity of reducing the clinical and economic burden of CF. Therefore, new evidence and value-based economic evaluations, that also take into account a social perspective, are needed to support the decision-making process. Key messages • The use of new health economic models is needed to guide the policy-makers in a value-based evaluation of Cystic Fibrosis treatments that take into account their whole value. • The assessment of the socio-economic burden of Cystic Fibrosis could guide the identification of the main actions to be implemented to respond adequately to the real health needs of patients.

Associations between income level and health outcomes in people with cystic fibrosis in Turkey

The Impact of Cost of Living on the Quality of Life of Cystic Fibrosis Patients: A Study in Greece

Education, employment, and income among people living with cystic fibrosis across three decades – A matched cohort study using Danish health registries

Emotional health in children and adolescents with cystic fibrosis

Polish Cystic Fibrosis Patients' Health-Related Quality of Life and Its Influencing Factors: A Cross-Sectional, Single-Centre Study

The effect of coronavirus disease 2019 on anxiety levels of children with cystic fibrosis and healthy peers

Comparison of refugee patients with cystic fibrosis and their counterpart children from Turkey during the war

Lower physical activity levels in youth with Cystic Fibrosis compared to healthy controls: A multicentre comparative study

Expanding the Impact of New Cystic Fibrosis Therapies in Low‐ and Middle‐Income Countries

Higher Levels of Education Are Associated With Full-Time Work in Adults With Cystic Fibrosis

More social support for physical activity improves functional capacity in children with cystic fibrosis

Assessment of patients' baseline cystic fibrosis knowledge levels following translation and adaptation of the CF R.I.S.E translation program into Turkish

Physical Activity and Sedentary Behavior in Adults With Cystic Fibrosis: Association With Aerobic Capacity, Lung Function, Sleep, Well-Being, and Quality of Life

Exploring Turkey's mosaic of novel variants and complex alleles in cystic fibrosis genetics

Insights from the Italian Cystic Fibrosis Patient Registry

Exploring the complexity of cystic fibrosis (CF) and psychosocial wellbeing in the 2020s: Current and future challenges

Socio-economic burden of cystic fibrosis in Europe: a systematic review of cost of illness evidence

Comparison of clinical features of cystic fibrosis patients eligible but not on CFTR modulators to ineligible for CFTR modulators

Socioeconomic burden of cystic fibrosis in Canada

Depressive symptoms and associated socioeconomic and clinic factors: Three different years data from Türkiye

Challenges in the care of cystic fibrosis in low‐to‐middle income countries